Stocks Health care OKUR
NASDAQ · Health careOnKure Therapeutics, Inc. (OKUR)
It posted a net loss of $61.9M. In fiscal 2025 capital spending exceeded operating cash flow by $51.9M. At September 30, 2026 it held $151.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about OnKure Therapeutics, Inc.
- Net worth
- OnKure Therapeutics, Inc. has a market value (market cap) of $137.1M at the latest share price, and shareholders' equity of $157.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $0, with a net loss of $52.7M.
- Cash flow
- In fiscal 2025 operations used $51.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- OnKure Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What OnKure Therapeutics, Inc. does
OnKure Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OKUR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$59.5M | -$4.40 | -$51.9M |
| 2024 | $0 | -$52.7M | -$15.28 | -$51.2M |
| 2023 | n/a | -$35.3M | -$124.41 | -$34.8M |
| 2022 | n/a | -$52M | -$104.66 | -$47.7M |
| 2021 | n/a | -$39.8M | -$108.12 | -$38.2M |
| 2021 | n/a | -$19.5M | -$473.94 | -$18.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What OnKure Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- October 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 10, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
- August 4, 2026
Insider trades
What the people running OnKure Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 21, 2026 | Saccomano Nicholas APresident and CEO, Director | Sold | 87 | $258.8 |
| September 21, 2026 | Leverone Jason A.Chief Financial Officer | Sold | 302 | $898.2 |
| June 22, 2026 | Saccomano Nicholas APresident and CEO, Director | Sold | 86 | $378.1 |
| June 22, 2026 | Leverone Jason A.Chief Financial Officer | Sold | 303 | $1.3K |
| March 23, 2026 | Saccomano Nicholas APresident and CEO, Director | Sold | 86 | $357.5 |
| March 23, 2026 | Leverone Jason A.Chief Financial Officer | Sold | 301 | $1.3K |
| December 31, 2025 | Mathers Edward TDirector | Received as pay | 3,911 | - |
| December 31, 2025 | Manke IsaacDirector | Received as pay | 5,258 | - |
Who owns OKUR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| AI Biotechnology LLC13D, may seek influence with 3 related filers | 19.99% | April 7, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | April 7, 2026 |
| Anders Hove13G, passive with 4 related filers | 9.5% | April 1, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 8% | August 14, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 6.67% | October 7, 2026 |
| StepStone Group LP13G, passive with 2 related filers | 6.6% | April 7, 2026 |
| Shay Capital LLC13G, passive with 1 related filers | 6.3% | May 29, 2025 |
| ADAR1 Capital Management, LLC13G, passive with 2 related filers | 5.5% | August 14, 2026 |
| Cantor Fitzgerald Securities13G, passive with 3 related filers | 5.2% | August 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 75 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 3,998,333 | 0 |
| Bvf Inc | 3,235,778 | +1,256,806 |
| Acorn Capital Advisors, LLC | 2,839,674 | 0 |
| StepStone Group LP | 2,660,612 | 0 |
| ADAR1 Capital Management, LLC | 2,238,684 | -196,257 |
| Vivo Capital, LLC | 1,927,710 | 0 |
| Vestal Point Capital, LP | 1,825,699 | -14,120 |
| BlackRock, Inc. | 1,499,845 | +1,450,258 |
| Trails Edge Capital Partners, LP | 1,438,456 | new |
| Vanguard Capital Management LLC | 1,437,039 | +854,562 |
| Adage Capital Partners GP, L.L.C. | 1,204,819 | 0 |
| Citadel Advisors LLC | 1,187,047 | +1,149,460 |
| Sio Capital Management, LLC | 1,078,965 | 0 |
| Prosight Management, LP | 978,992 | -1,175,389 |
| Logos Global Management LP | 963,855 | new |
| Geode Capital Management, LLC | 724,438 | +625,688 |
| NEA Management Company, LLC | 478,548 | 0 |
| State Street Corp | 463,662 | +450,200 |
| Ensign Peak Advisors, Inc | 431,631 | new |
| Renaissance Technologies LLC | 358,738 | -18,512 |
Insiders
4 insiders reported holding 65,553 shares in total, about $221.9K at the last price.
| Holder | Shares |
|---|---|
| Manke IsaacDirector | 20,583 |
| Leverone Jason A.Chief Financial Officer | 18,500 |
| Mathers Edward TDirector | 15,310 |
| Saccomano Nicholas APresident and CEO, Director | 11,160 |
Questions about OKUR
What does OnKure Therapeutics, Inc. do?
OnKure Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as OKUR. Its shares trade on NASDAQ under the ticker OKUR.
What is OnKure Therapeutics, Inc.'s net worth?
OnKure Therapeutics, Inc. has a market value (market cap) of $137.1M at the latest share price, and shareholders' equity of $157.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is OnKure Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $61.9M.
When did OnKure Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is OnKure Therapeutics, Inc.'s next earnings report?
OnKure Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare OKUR with
Follow OKUR
Get an email when OnKure Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values OnKure Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.